Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validation

Erin K Nyren-Erickson¹, Michael Bouton⁴, Mihir Raval³, Jessica Totzauer², Sanku Mallik¹ and Neville Alberto⁴*.

Abstract

Background: The ADAMs (A Disintegrin and Metalloproteinases) are a family of multi-domain, zinc-dependent metalloproteinase enzymes. ADAM 12 has been previously associated with the onset and progression of breast cancer, and elevated levels of ADAM 12 have been previously found in the urine of breast cancer patients. Aims of the current study are: 1) establish the viability of urinary ADAM 12 as a diagnostic marker for breast cancer, and 2) explore the effects of surgical tumor removal on the levels of urinary ADAM 12.

Methods: A total of 96 patients have been recruited for this study, including 50 patients diagnosed with cancer, and 46 age-matched controls. Commercially available ELISA kits for ADAM 12 were used to quantify the presence and concentration of this enzyme in the urine from cancer patients with ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC) both prior to any treatment and approximately two weeks following surgery, as well as from controls.

Results: We find no statistically significant differences between the concentrations of ADAM 12 in the urine of breast cancer patients prior to treatment and that of their age-matched controls; however the concentration of ADAM 12, both alone and as a function of urine total protein, are significantly elevated following surgery (p < 0.0001). Patients who underwent a mastectomy have significantly higher urinary ADAM 12 concentrations than those who underwent a lumpectomy (significant at p = 0.0271).

Conclusions: These findings suggest that urinary ADAM 12 may not correlate directly with the status and stage of breast cancer as previously thought; rather these increases may be a result of tissue injury and inflammation from biopsy and surgical resection. Results of this study may suggest a need for biomarkers to be evaluated carefully in the context of tissue damage.

Keywords: A Disintegrin and Metalloproteinase, ADAM12, ADAM12-S, Breast cancer, Cancer biomarker

Background

Breast cancer is currently the second leading cause of cancer deaths among women in the United States (second only to lung cancer), and it is now estimated that in the U.S. one in eight women will be diagnosed with breast cancer during her lifetime [1]. However, if breast cancer is detected during its earlier stages, the 5-year survival rate may be as high as 93% (at stage 0; this reflects death from all causes); when detected at stage IIB and later, 5-year survival rate drops below 50% [2], making early detection of breast cancer essential for favorable prognosis. Tumor markers currently in use in the evaluation of breast cancer include (but are not limited to) cancer antigen 15-3 [3,4] and 125 [5] (CA15-3, CA 125), carcinoembryonic antigen [3,4] (CEA), and prolactin [6]; however these show little potential for early detection [7]. Recent studies have begun exploring the potential of urinary biomarkers for
breast cancer detection [8,9], and among those studied are the ADAM proteases [10], particularly ADAM 12 [11-13].

The ADAMs (A Disintegrin and Metalloproteinases) are a family of multi-domain, zinc-dependent metalloproteinase enzymes. There are currently 40 known genes for ADAMs, 21 of which are known to function in humans [14]. ADAMs are usually membrane bound (although some members of the ADAM family have secreted forms, including ADAM-9 [15], -10 [16], -12 [17] and -28 [18-20]), and their physiological roles include extracellular matrix restructuring [21-23], cell adhesion [24-26], and cell-surface protein processing [27-29]. ADAM 12, which is transcribed as both a membrane bound (ADAM 12-L) and a secreted form (ADAM 12-S), has roles in cell adhesion and matrix restructuring during cell differentiation [24-26,30], and also has regulatory functions [31] in healthy tissues. ADAM 12 has also been associated with development and progression of a number of disease states, including arthritis [32], cardiac hypertrophy [33], liver fibrogenesis [34], and various cancers, including bladder [35], lung [36], brain [37] and breast [11]. It has also been suggested that the ADAM 12 produced by the tumor cells drives the progression of breast tumors [38]. Further, a study conducted in 2012 correlates gene expression of both ADAM 12 and ADAM 17 with clinical and pathological characteristics of breast cancer [39].

One study in 2004 indicated a strong correlation between excretion of urinary ADAM 12 and breast cancer status and stage [11]. This report concluded that patients with ductal carcinoma in situ (DCIS), invasive breast cancer (IBC), and metastatic breast cancer had significantly higher levels of ADAM 12 present in their urine than controls (i.e. patients with “no discernible disease”) [11]. The report further concluded that only 15% of the control subjects had detectable levels of ADAM 12 present in their urine, while 82%, 86%, and 85% of patients with DCIS, IBC and metastatic disease, respectively, were positive for the presence of ADAM 12 [11]. These results strongly suggest that a urine test for ADAM 12 would prove especially useful for the diagnosis of breast cancers, stage DCIS and later.

The aims of the current study are twofold: 1) establish the viability of urinary ADAM 12 as a diagnostic marker for breast cancer, and 2) explore the effects of surgical tumor removal on the levels of urinary ADAM 12. We hypothesize that, as previous reports suggest that breast tumor progression is responsible for the increased ADAM 12, the urinary ADAM 12 concentrations will be significantly higher in cancer patients than controls, and that urinary ADAM 12 levels will decrease following tumor removal. Our primary objective is to establish a simple, practical test for the early detection of breast cancer. As such, we have chosen to utilize commercially available ELISA kits for urinary ADAM 12 measurements: we reason that they are a well accepted technology, which will provide reliable, reproducible results in a clinic setting.

Methods

Ethics review and approval

This study was conducted in compliance with the Helsinki Declaration. The protocol, informed consent form, and laboratory manuals for this study were reviewed and approved by the Sanford Health Institutional Review Board in compliance with its Federalwide Assurance (#00016819). All participants’ participation was voluntary, and all enrolled participants were given the right to refuse or exit the study at any time. Participants were given a unique study number; and therefore their specimens and related medical information were de-identified. Participant’s study related medical record information was protected in accordance with HIPAA regulation.

Materials

Coomassie Blue (Bradford) Assay Kit was obtained from Thermo Scientific (Rockford, IL), and 96-well polystyrene plates for this assay were obtained from Greiner Bio-One (Monroe, NC). ADAM 12 enzyme linked immunosorbent assay (ELISA) kits obtained from R&D Systems (Minneapolis, MN). All supplies used without any further modifications.

Patient recruitment

Study participants were screened during their visit either to the Sanford Breast Clinic and/or breast surgeon consultation visit by their treatment provider. If they wished to participate in the study, the clinical research coordinator met with them to discuss and/or complete the Informed Consent Form (ICF) document and process. After consent was obtained, the coordinator collected the pre-surgery or control urine sample, and informed those participants with breast cancer of the need to leave a second sample at a follow-up visit after their surgery. Control patients were matched for age and co-morbidities. They were selected from Sanford Medical Center Breast Clinic or other clinics. If they had benign and non-interventional breast findings they were approached at their clinic visit about participation in the study and appropriately consented. Controls were consented using the same ICF document and process as breast cancer subjects.

Inclusion criteria:

- Females age 21 years of age or older
- Recent diagnosis of breast cancer
- No previous diagnosis of cancer, excepting non-melanoma skin cancer.
Treatment naïve (i.e., no chemotherapy or radiation therapy prior to surgery for this breast cancer diagnosis)

Exclusion criteria:

- Pregnancy
- Advanced stage breast cancer disease (i.e., stage 4 cancer with multiple metastasis)

Age-matched controls were females with no positive history of breast cancer or other previous diagnosed cancers, excluding non-melanoma skin cancer. All patients were recruited for study from the Sanford Medical Breast Clinics, and were consented in accordance with institutional regulatory board guidelines. All breast cancer patients had surgery as their initial treatment. The surgeries involved either a lumpectomy or a mastectomy for local control of their cancer; and in most cases axillary sentinel lymph node dissection was included. When indicated, a level I and II axillary lymph node dissection was done as part of the same procedure based on frozen section evaluation on the sentinel lymph nodes. The decision of surgery options was made after multidisciplinary treatment planning, consultation with the patients, and followed National Cancer Cooperative Network (NCCN) guidelines.

Urine collection and processing

Following consent, patients and controls were brought to a private area and asked to leave a urine sample. Immediately following collection, the urine was well mixed, and ten milliliters (10 mL) was aliquoted into a sterile, 10 mL screw cap test tube, and labeled with the patients de-identified information only; available information includes only patient age, stage of cancer, tumor size and co-morbidities. These samples were immediately placed upright in a -80°C freezer for storage. Recruited breast cancer patients provided two samples of urine, one just following diagnosis, and a second approximately two weeks following surgery to remove the tumor mass (all patients recruited for this study were scheduled for surgery). Controls have provided one sample only. Upon collection of 20 samples, tubes were transported to North Dakota State University on dry ice for testing.

Prior to testing, samples were thawed on ice and centrifuged at 200 rcf for 15 minutes to remove any particulates. The resulting supernatant was diluted 1:5 in one of two buffers: for the Bradford assay, 50 mM Tris at pH 8 was used, and for ELISA the calibrator diluent provided with the kit was used, as per the manufacturer’s suggestion. Preliminary data demonstrated the necessity of dilution such that the patient samples would fit within the standard curve of both the Bradford assay and the ADAM 12 ELISA.

Bradford assay

Manufacturer’s instructions for the “micro microplate procedure” obtained with the kit were followed regarding volumes of samples, standards, and assay reagent. Bovine serum albumin was provided with the kit, and was used to produce the standard curve. The 2 mg/mL albumin standard was diluted in 50 mM Tris buffer (pH 8) to produce a standard curve ranging from zero μg/mL to 100 μg/mL. Twenty patient and/or control urine samples diluted 1:5 (see Section on Urine collection and processing) were loaded into four wells each of a 96-well standard clear bottom polystyrene plate, 150 μL per well. Standard samples were also loaded, two wells each sample, 150 μL per well. Bradford assay reagent provided was loaded into each well, 150 μL per well, and the plate was mixed on a shaker for 10 seconds, followed by incubation at room temperature for 10 minutes. Reading of plate absorbance, production of the standard curve and analysis of the samples was performed according to manufacturer’s instructions.

Table 1 Urinary ADAM 12 of cancer patient group vs. control group

|                       | Cancer group: pre-surgery | Cancer group: post-surgery | Control group |
|-----------------------|---------------------------|---------------------------|---------------|
|                       | (n = 50)                  | (n = 49)                  | (n = 46)      |
| Age                   | Mean: 60.9 ± 13.0         | Mean: 60.9 ± 13.0         | Mean: 60.1 ± 12.4 |
|                       | Median: 60               | Median: 60               | Median: 60    |
| [ADAM 12] (ng/mL)     | Mean: 3.36 ± 3.04        | Mean: 16.3 ± 15.6        | Mean: 3.52 ± 3.17 |
|                       | Median: 2.48             | Median: 10.3             | Median: 2.77  |
| Total protein (μg/mL) | Mean: 60.7 ± 53.6        | Mean: 59.7 ± 32.9        | Mean: 78.6 ± 65.6 |
|                       | Median: 42.0             | Median: 59.0             | Median: 58.7  |
| ADAM 12 as % of total protein | Mean: 0.008 ± 0.01 | Mean: 0.03 ± 0.03 | Mean: 0.006 ± 0.006 |
|                       | Median: 0.005            | Median: 0.017            | Median: 0.004 |

Cancer group consists of DCIS (n = 15) and IBC (n = 35) diagnoses.
ELISA
Twenty patient and/or control urine samples diluted 1:5 (see section on urine collection and processing) were loaded into four wells each of the provided 96-well plate of a commercially available ELISA kit. Standard samples were also loaded, two wells each. Manufacturer’s instructions were followed for production of standard curve and analysis of samples. The antibodies provided with this kit consist of monoclonal antibodies specific for ADAM 12.

Statistical analysis
Groups were compared using non-parametric Mann-Whitney test ($\alpha = 0.05$). Analysis was performed using Minitab (v. 16.1.1).

Results
A total of 50 patients with the diagnosis of breast cancer and 46 age matched control patients were recruited into the study. Based on the data collected, no significant differences exist between the urinary ADAM 12 concentrations of the control patients and the cancer patients prior to their surgery. The urinary concentration of ADAM 12 increased significantly following patient surgery ($p < 0.0001$), both in ng/mL and as a function of total urine protein. Results are summarized in Table 1 and Figure 1 below.

The cancer patients recruited for this study consist of 15 women with a diagnosis of DCIS, and 35 women with a diagnosis of IBC (30% and 70% of the total group, respectively). If we consider these as separate groups and compare these groups individually to the control group the results do not change, nor do the DCIS and IBC patients differ significantly from each other pre-surgery (see Figure 2). The ADAM 12 concentration ranges and median changes in concentration from pre- to post-surgery are also consistent between the DCIS and IBC groups (see Table 2). Significant elevation of urinary ADAM 12 does take place after patients have undergone surgery (overall $p$-value $< 0.0001$).

Results further suggest a link between the extent of patient surgery and urinary ADAM 12 elevation. Of the cancer patients recruited for this study, 38 of these underwent lumpectomies, and 11 underwent mastectomies (77.6% and 22.4% of the total group, respectively; one of
the recruited patients failed to leave a post-operative sample. The concentration of ADAM 12 in the urine of mastectomy patients was significantly higher than that of lumpectomy patients post-surgery (p = 0.0075); the median increase in ADAM 12 concentration for mastectomy patients was 14.7 ng/mL versus 4.8 ng/mL for lumpectomy patients. The median percent increase in urinary ADAM 12 concentration following surgery was 313.6% for lumpectomy patients, and 764.5% for mastectomy patients. When considered as a percentage of total protein, the percent urinary ADAM 12 following a mastectomy versus that following a lumpectomy was significant at p = 0.0013. There were no statistically significant differences between the total urine protein concentrations of these groups. These results are summarized in Table 3 and Figure 3. There were no significant differences between the urinary ADAM 12 concentrations of lumpectomy and mastectomy patients prior to their surgeries (data not shown).

Discussion

Interestingly, the current results appear to contradict those published in 2004 [11]; while these authors have concluded that patients with DCIS and IBC had significantly higher levels of ADAM 12 in their urine, our data shows no significant difference between the cancer and control groups. It should here be noted that this group has evaluated the patient concentration of urinary ADAM 12 by western blot, and they have used polyclonal antibodies directed against the cysteine rich domain of ADAM 12 in their analysis [11,35]. We believe that this difference in technique alone should not have resulted in these significant variations in results.

In addition, there is also an apparent conflict between the current results and those published in 2012 [39]. These authors have observed an increase in the genetic expression of both ADAM 12 and ADAM 17 in malignant breast tissue. However, it should be noted that their results also suggest that the expression levels of ADAM 12-L (the membrane bound form) are considerably more elevated than those of ADAM 12-S (the secreted form)
With regard to protein expression, Narita, et al. do not distinguish between ADAM 12-L and ADAM 12-S. This suggests that the elevation of ADAM 12 protein seen during this study was likely primarily elevation of ADAM 12-L, and as this form is membrane bound, it is far less likely to end up in the patient’s urine.

The current results raise a number of interesting questions. The observed elevation in ADAM 12 following surgery is not surprising: many matrix metalloproteinase enzymes are upregulated during wound healing [40], and evidence suggests that ADAM 12 is involved in tissue remodeling [41], making it likely to undergo upregulation following surgical or other trauma to the tissues. We also note a priori that many patients recruited for this study have co-morbidities which may affect levels of ADAM 12 (e.g. osteoarthritis [32], allergic rhinitis [42], and asthma [43]; however these co-morbidities are well balanced between the cancer group and the control group, and based on our analysis they have had no significant effect on the concentrations of urinary ADAM 12. The data also shows that some cancer and control patients having levels of ADAM 12 above the median did not have obvious co-morbidities. It remains to be determined under what circumstances members of a certain group could have significantly elevated levels of urinary ADAM 12 compared to members of another group, assuming these groups are age-matched. Based on our observations, these circumstances could easily occur if the group having elevated urinary ADAM 12 had undergone surgery within four weeks of having been tested. Further, as those patients with more advanced stages of cancer would be likely to have had more extensive surgery; it would follow that those patients with higher stage breast cancers would appear to have higher urinary ADAM 12 concentrations. Other tissue trauma could also play a role, such as biopsies. Further, if existing co-morbidities had not been well balanced between the control and test groups, it is likely these could have played a role in the elevation of urinary ADAM 12 levels in one group over another.

As a final consideration we note that in 2011, the same group (which concluded in 2004 that DCIS patients have significantly elevated urinary ADAM 12 vs. controls) has conducted another study (utilizing fluorescent metalloproteinase substrates) to simultaneously detect a number of matrix metalloproteinases (MMP-1, -2, -3, -8, -9, and -13) and ADAMs (ADAM-8, -9, -10, -12, and -17) in the urine of cancer patients and age-matched controls. This study concluded that no statistical difference exists between DCIS patients and age-matched controls when this polymer-based method is used [12]. Due to these contradictory results, further studies are necessary in order either to accept or to reject the measurement of urinary ADAM 12 as a viable method for the diagnosis of breast cancer.
Conclusions
We find no significant difference between urinary ADAM 12 concentrations in patients diagnosed with DCIS or IBC and their age-matched controls prior to any surgery or other therapeutic treatment. Further, we find no significant differences in urinary ADAM 12 concentrations between DCIS patients and IBC patients either prior to or following surgical treatment. These results are in contrast to those published by another group in 2004 [11].

Following surgical treatment, the concentrations of urinary ADAM 12 are elevated significantly over age-matched controls, and the degree of this increase depends upon the extent of the surgery.

These conclusions suggest that an increase in the concentration of urinary ADAM 12 may not correlate directly with the status and stage of breast cancer as previously thought; rather these increases may be a result of tissue injury and inflammation from biopsy and surgical resection. Further studies are necessary to accept or reject the measurement of urinary ADAM 12 as a viable method for the diagnosis of breast cancer.

The above results may suggest a need for biomarkers to be evaluated carefully in the context of tissue damage.

Abbreviations
ADAM12: A disintegrin and metalloproteinase isofom 12; DCIS: Ductal carcinoma in situ; IBC: Invasive breast cancer; ELISA: Enzyme-linked immunosorbent assay.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
ENE was involved in study design, carried out ELISA and Bradford assays, compiled data, conducted data analysis and interpretation, and drafted the manuscript. MR assisted in patient recruitment, contributed to experimental design, and assisted in manuscript revision. JT assisted with ELISA procedures, data acquisition, and data interpretation. MM assisted with IRB submission, manuscript review, and study design. SM provided laboratory facilities, assisted with study design and manuscript review. NA conceived of the study, secured the grant for the study, organized facilities for patient recruitment, and approved manuscript drafting and submission. All authors read and approved the final manuscript.

Acknowledgments
We would like to thank Abby Zimmerman for her contributions as a study coordinator, and for her assistance consenting and coordinating the patients. We thank BreAnn Neiger for compiling information regarding patient surgeries. Support provided by the Sanford Seed Grant Research Fund, Grant# 2012-211.

Author details
1Department of Pharmaceutical Sciences, Fargo, ND 58108-6050, USA.
2Department of Pharmacy Practice, North Dakota State University, Fargo, ND 58108-6050, USA. "Essentia Health, Fargo, ND 58103, USA. "Roger Maris Cancer Center, Sanford Health, Fargo, ND 58122, USA.

Received: 20 December 2013 Accepted: 18 March 2014 Published: 1 April 2014

References
1. National Breast Cancer Statistics. www.komenneohio.org.
2. Breast Cancer Survival Rates by Stage. www.cancer.org.

3. Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Canc 2005, 5(11):845–856.
4. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC, Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klees GG, Larsson R, Loogjegde LH, Molina R, Nielsen HJ, Rittenhouse H, Shih lE M, Sibicky P, Soektornis G, Stephan C, Sokol L, Hoffman BR, Diamandis EP: National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54(12):e11–e79.
5. Norum LF, Erktein B, Nustad K: Elevated CA125 in breast cancer—A sign of advanced disease. Tumour Biol 2001, 22(4):223–228.
6. Tivorgar SS, Ellassan AH, Suss P, Hankinson SE: A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007, 25(12):1482–1488.
7. Opstal-van Winden AW, Rodenburg W, Pennings J, van Oostrom CT, Beijnen JH, Peeters PH, van Gils CH, de Vries A: A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci 2012, 13(10):1387–1390.
8. Nolen BM, Lokshin AE: The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid. Int J Mol Markers 2011, 26(3):141–152.
9. Silva CL, Passos M, Camara JS: Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers—a powerful strategy for breast cancer diagnosis. Talanta 2012, 81(5):356–368.
10. Trad A, Hansen HP, Sibisky P, Kraus K, Hedin M, Yamamoto K, Mauermann A, Desel C, Lorenzen I, Lemke H, Rose-John S, Grotzinger J: ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates. Cancer Immunol Immunother 2013, 62(3):411–421.
11. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA: ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004, 279(49):51323–51330.
12. Roy R, Zurakowski D, Pories S, Moss M, Moses M: Potential of fluorescent metalloproteinase substrates for cancer detection. Clin Biochem 2011, 44:1434–1439.
13. Ray BK, Dhar S, Henry C, rich A, Ray A: Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family. Canc Res 2013, 73(2):736–744.
14. Nyren-Erickson EK, Jones JM, Srivastava DK, Mallik S: A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications (in press). Biochips Biochip Acta General Subject 2013, 1830(10):4444–4455.
15. Hotoda N, Koike H, Sasagawa N, Ishiura S: A secreted form of human ADAM9 has an alpha-secretase activity for APP. Biochem Biophys Res Commun 2002, 293(2):800–805.
16. Yavari R, Adida C, Bray-Pard W, Brines M, Xu T: Human metalloprotease-disintegrin Kuzubanian regulates sympathetic neural cell fate in development and neoplasia. Hum Mol Genet 1998, 7(1):1161–1167.
17. Gipirin BJ, Loecheil F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM: A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 1998, 273(1):157–166.
18. Roberts CM, Tani PH, Bridges LC, Laszik Z, Bowditch RD: MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes. J Biol Chem 1999, 274(41):29251–29259.
19. Hooper NM, Lenzdecke U: The Adam family of proteases. Dordrecht: Springer; 2005.
20. Seals DF, Courtridge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003, 17(17):30–37.
21. Millipip Ml, Dallas DJ, Wu E, Dale S, McKie N: The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 1998, 251(2):594–598.
22. Alenkadi D, Cousin H, Gaullier T, Smith K, White JM, Dambere T, DeSimone DW: Xenopus ADAM 13 is a metalloprotease required for cranial neural crest-cell migration. Curr Biol 2001, 11(2):918–930.
23. Martin J, Eynstone J, Davies M, Williams JD, Steadman R: The role of ADAM 15 in glomerular mesangial cell migration. J Biol Chem 2002, 277(37):33683–33689.
24. Zoltskovska A: Disintegrin-like/cysteine-rich region of ADAM 12 is an active cell adhesion domain. Exp Cell Res 1999, 252(2):425–431.

Nyren-Erickson et al. Journal of Negative Results in BioMedicine 2014, 13:5
http://www.jnrbm.com/content/13/1/5 Page 7 of 8
25. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM: Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 1999, 154(5):1489–1501.

26. Iba K, Albrechtsen R, Gilpin B, Frohlich C, Loechel F, Zolkiewska A, Ishiguro K, Kojima T, Liu W, Langford JK, Sanderson RD, Brakebusch C, Fassler R, Wewer UM: The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J Cell Biol 2000, 149(5):1143–1156.

27. Selvais C, D’Auria L, Tyteca D, Perrot G, Lemoine P, Troebel L, Dedieu S, Noel A, Nagase H, Henriot P, Courtoy PJ, Marbaix E, Emonard H: Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J 2011, 25(8):2770–2781.

28. Saftig P, Hartmann D: ADAM10: A Major Membrane Protein Ectodomain Shedding Involved in Regulated Intramembrane Proteolysis. Dordrecht, The Netherlands: Springer; 2005.

29. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israel A: A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000, 5(2):207–216.

30. Kawaguchi N, Sundberg C, Kveiborg M, Moghadaszadeh B, Asmar M, Dietrich N, Thodeti CK, Nielsen FC, Moller P, Mercurio AM, Albrechtsen R, Wewer UM: ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function. J Cell Sci 2003, 116(Pt 19):3893–3904.

31. Staatz D, Sanjay A, Hansen MT, Albrechtsen R, Wewer UM, Kveiborg M: ADAM12 localizes with c-Src to actin-rich structures at the cell periphery and regulates Src kinase activity. Exp Cell Res 2010, 316(1):55–67.

32. Okada A, Mochizuki S, Yatabe T, Kimura T, Shiomi T, Fujita Y, Matsumoto H, Sehara-Fujisawa A, Iwamoto Y, Okada Y: ADAM-12 (meltrin alpha) is involved in chondrocyte proliferation via cleavage of insulin-like growth factor binding protein 5 in osteoarthritic cartilage. Arthritis Rheum 2008, 58(3):778–789.

33. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan BA, Schulz R, Kasiri Z, Lopaschuk GD, Fernandez-Patron C: Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009, 119(18):2483–2489.

34. Bourd-Boittin K, Le Pabic H, Bonnier D, L’Helguich A, Theret N: RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis. J Biol Chem 2008, 283(38):26000–26009.

35. Frohlich C, Albrechtsen R, Dysjkot L, Rudkjær L, Omtoft TF, Wewer UM: Molecular profiling of ADAM12 in human bladder cancer. Clin Canc Res 2006, 12(24):7359–7368.

36. Mino N, Miyahara R, Nakayama E, Takahashi T, Takahashi A, Iwasaki S, Sonobe M, Okubo K, Hirata T, Sehara A, Date H: A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. J Surg Oncol 2009, 100(3):267–272.

37. Kanakis D, Lendeckel U, Theodosiou P, Dobrowolski H, Mawrin C, Kellhoff G, Bukwoka A, Dietmann K, Bogerts B, Bernstein HG: ADAM12: a putative marker of oligodendrogliomas? Diag Markers 2013, 34:81–91.

38. Frohlich C, Nehammer C, Albrechtsen R, Kronqvist P, Kveiborg M, Sehara-Fujisawa A, Mercurio AM, Wewer UM: ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression. Mol Canc Res 2011, 9(11):1449–1461.

39. Nanta D, Seclaman E, Unionou S, Anghel A: Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics. Acta Histochem 2012, 114(2):131–139.

40. Veeravalli KK, Dasari VR, Tsung AJ, Dinh DH, Gujrati M, Fassett D, Rao JS: Human umbilical cord blood stem cells upregulate matrix metalloproteinase-2 in rats after spinal cord injury. Neurobiol Dis 2009, 36(1):200–212.

41. Kim J, Kim H, Lee SJ, Choi YM, Lee JY: Abundance of ADAM-8, -9, -10, -12, -15 and -17 and ADAMTS-1 in mouse uterus during the oestrous cycle. Reprod Fertil Dev 2005, 17(5):543–555.

42. Estrella C, Rocks N, Paulissen G, Quesada-Calvo F, Noel A, Vlain E, Lassalle P, Tillie-Leblond I, Cataldo D, Gossett P: Role of A disintegrin and metalloproteinase-12 in neutrophil recruitment induced by airway epithelium. Am J Respir Cell Mol Biol 2009, 41(4):449–458.

43. Paulissen G, Rocks N, Quesada-Calvo F, Gossett P, Foidart JM, Noel A, Louis R, Cataldo DO: Expression of ADAMs and their inhibitors in sputum from patients with asthma. Mol Med 2006, 12(7–8):171–179.